The FDA Tuesday approved Samsung Bioepis’ Hadlima (adalimumab-bwwd), referencing Humira.
This article has been updated.
The FDA on Tuesday approved Samsung Bioepis’ Hadlima (adalimumab-bwwd), referencing Humira.
Hadlima, a subcutaneous injection, was cleared for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.
"With the approval of Hadlima, we are proud to have three anti-TNF biosimilars approved in the US. We believe the US healthcare system can benefit from biosimilars, which could play a critical role in broadening access to treatment options for patients with autoimmune conditions across the country," said Hee Kyung Kim, senior vice president and head of regulatory affairs, Samsung Bioepis, in a statement. “We remain committed to advancing our strong pipeline of biosimilar candidates, so that more patients and healthcare systems can benefit from biosimilars.”
A pivotal pharmacokinetic (PK) study of the biosimilar in healthy volunteers was conducted in Germany. This study was a randomized, single-blind, 3-arm, parallel group, single-dose phase 1 study in 189 healthy volunteers who were randomized to receive the biosimilar or the reference. All of the 90% confidence intervals (CIs) for the geometric least squares means ratios of primary PK parameters for the biosimilar and the EU and US reference products fell within the prespecified equivalence margin of 0.8 to 1.25.
The biosimilar was also studied in a phase 3 study in patients with moderate to severe rheumatoid arthritis. In the study, patients who failed to respond adequately to methotraxate were randomized to receive the biosimilar (n = 269) or the reference (n = 273) at a dose of 40 mg every other week. The primary efficacy end point was the response rate based on the American College of Rheumatology 20% improvement criteria (ACR20) at week 24.
The ACR20 response rate at week 24 was equivalent between the 2 arms (72.4% and 72.2%, respectively), and the difference in ACR20 response rate was 0.1% (95% CI, −7.83% to 8.13%) within the prespecified equivalence margin of plus or minus 15%. Both adalimumabs were well tolerated and had comparable safety profiles.
The biosimilar is also approved in the European Union, where it has launched in numerous markets. However, Samsung Bioepis and Biogen, with partner Merck, will not be free to launch the product in the United States until June 30, 2023, under the terms of a patent litigation settlement with Humira’s sponsor, AbbVie.
Hadlima, which is approved as Imraldi in the European Union, joins Amgen’s Amjevita, Boehringer Ingelheim’s Cyltezo, and Sandoz’s Hyrimoz as FDA-approved, but unlaunched, biosimilar adalimumab products.
Earlier in the day Tuesday, the FDA approved Pfizer’s rituximab biosimilar, Ruxience (rituximab-pvvr), referencing Rituxan.
References
1. Shin D, Kim Y, Kim HS, Fuhr R, Kornicke T. A phase 1 pharmacokinetic study comparing SB5, an adalimumab biosimilar, and adalimumab reference product (Huimra) in healthy subjects. Ann Rheum Dis. 2015;74:459-460. ard.bmj.com/content/74/Suppl_2/459.3.info
2. Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III Randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate‐to‐severe rheumatoid arthritis. Arthritis Rheumatol. 2018; 70(1):40-48. doi: 10.1002/art.40336.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.